ペプチド原薬の世界市場

ペプチド原薬の世界市場は2030年までに335億米ドルに到達

2024年に109億米ドルと推定されるペプチド原薬の世界市場は、分析期間2024-2030年にCAGR 20.5%で成長し、2030年には335億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるGLP-1受容体作動薬は、CAGR 19.9%を記録し、分析期間終了時には176億米ドルに達すると予測されます。インスリンセグメントの成長率は、分析期間中CAGR 21.8%と推定されます。

米国市場は30億米ドルと推定、中国はCAGR27.4％で成長予測

米国のペプチド原薬市場は2024年に30億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに79億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは27.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ16.5％と18.3％と予測されています。欧州では、ドイツがCAGR約17.2%で成長すると予測されています。

世界のペプチド原薬市場- 主要動向と促進要因のまとめ

なぜペプチド原薬は創薬と治療イノベーションにおいて戦略的重要性を増しているのか？

ペプチド原薬（API）は、幅広い治療適応症において高い特異性、効力、安全性を提供し、現代の医薬品開発において最も有望なセグメントの一つとして浮上しています。アミノ酸の短い鎖から誘導されるペプチドAPIは、生物学的に活性な化合物で、内因性分子を模倣し、受容体、酵素、イオンチャネルなどの特定の標的と相互作用します。そのユニークな作用機序、良好な薬物動態、低毒性により、がん、代謝性疾患、心血管系疾患、希少遺伝性疾患の治療において高い価値があります。

リラグルチド、セマグルチド、ブセレリン、リュープロリドといったペプチドベースの医薬品が成功を収めていることから、ペプチドの臨床的有用性が証明され、製薬企業は専門的な研究開発と拡張可能な製造プラットフォームに投資するようになりました。精密医療と生物学的製剤へのシフトに伴い、ペプチドは低分子と大型タンパク質の間のギャップを埋めつつあり、細胞透過性ペプチド、ペプチド-薬物複合体、多機能ペプチドなどの新規治療法の機会を提供しています。臨床段階におけるペプチド治療薬のパイプラインの拡大は、高純度でコスト効率の高いペプチド原薬に対する需要の高まりを裏付けています。

合成技術とプロセス最適化の進歩は、原薬製造能力をどのように向上させているか？

固相ペプチド合成（SPPS）、液相合成、ハイブリッド技術の進化により、ペプチド原薬製造のスケーラビリティ、純度、スループットが大幅に改善されました。自動化されたペプチド合成機、改良された樹脂、最適化されたカップリング試薬により、反応時間や廃棄物の発生を減らし、長く複雑な環状ペプチドの効率的な合成が可能になりました。さらに、分取HPLC、イオン交換クロマトグラフィー、限外ろ過などの精製技術の革新により、収率と不純物のコントロールが向上しました。

メーカー各社は、連続製造プラットフォームやハイスループットパラレル合成システムに投資することで、バッチのばらつきを抑え、臨床用や商業用の供給に向けた迅速なスケールアップを可能にしています。さらに、ICH Q11コンプライアンス、プロセスバリデーション、不純物プロファイリングに対する規制当局の期待が、高度な分析とQuality-by-Design（QbD）フレームワークの採用を促進しています。脂質化、PEG化、環化などのペプチド修飾戦略は、バイオアベイラビリティと安定性を高めるために原薬の段階で統合されつつあります。こうした進歩により、ペプチドのバリューチェーン全体にわたって、コスト効率、規制遵守、治療成績が向上しています。

どの治療領域と地域市場がペプチド原薬の世界需要を促進しているか？

代謝性疾患-特に2型糖尿病と肥満-は、GLP-1アナログの商業的成功を考えると、依然としてペプチド原薬の主要な治療ドライバーです。腫瘍学、内分泌学、泌尿器学、生殖医療もまた、ホルモン調節、腫瘍抑制、標的治療デリバリーにペプチドを利用する主要な治療領域です。ペプチドは、希少疾病用医薬品の開発、ワクチン製剤、抗菌薬や抗ウイルス薬などの感染症管理にも使用されるようになってきています。

北米と欧州は、強力なバイオ医薬品パイプライン、高度な製造能力、規制の成熟度により、ペプチド原薬の消費を独占しています。米国は技術革新、臨床試験、商業化でリードしており、ドイツ、スイス、ベルギーは主要な製造拠点です。アジア太平洋（特にインド、中国、韓国、日本）は、ペプチド原薬と受託製造サービス（CDMO）のコスト効率の高いサプライヤーとして、急速にその足跡を広げています。各地域のプレーヤーは、ブランド革新企業とバイオシミラー開発企業の両方のニーズを満たすために規模を拡大しており、世界に統合された競合市場競争を形成しています。

ペプチド原薬市場の長期的成長と戦略的変革の原動力は？

ペプチド原薬市場の成長の原動力は、ペプチド医薬品の臨床成功率の上昇、生物製剤への旺盛な研究開発投資、標的治療への嗜好の高まりです。医薬品パイプラインが多様化し、規制当局が希少疾病用医薬品の開発を奨励する中、ペプチド原薬はスケーラブルで汎用性の高い治療プラットフォームとして台頭しつつあります。開発・製造受託サービス（CDMO）の世界の拡大も原薬のアウトソーシングを後押ししており、GMPに準拠したコスト競争力のある生産を行うために、ペプチドに特化した施設の需要が高まっています。

戦略的には、企業は垂直統合を採用し、共同開発のためにバイオテクノロジー企業と提携し、供給の弾力性のために二重製造拠点に投資しています。ペプチド合成が計算生物学、AIベースのドラッグデザイン、ナノテクノロジーと融合することで、個別化医療や先進デリバリーシステムに新たなフロンティアが開かれつつあります。規制の枠組みがペプチド治療薬に対応するよう進化し続ける中、堅牢な品質システムを備えた柔軟なエンド・ツー・エンドのソリューションを提供するAPIメーカーは、この高成長セグメントをリードする立場にあります。

セグメント

薬剤クラス別（GLP-1受容体作動薬、インスリン、その他のペプチドクラス）、投与経路別（経口経路、非経口経路）、用途別（2型糖尿病用途、1型糖尿病用途、肥満症用途、非アルコール性脂肪性肝疾患用途、その他の用途）

調査対象企業の例（注目の34社）

• Aji Bio-Pharma Services
• AmbioPharm, Inc.
• Anthem Biosciences
• Bachem Holding AG
• Biocon Limited
• Biopeptek Pharmaceuticals
• CordenPharma International
• CPC Scientific Inc.
• Creative Peptides
• GenScript Biotech Corp.
• Hybio Pharmaceutical Co.
• Innovent Biologics
• Lonza Group AG
• Merck KGaA
• Peptide Institute, Inc.
• PeptiDream Inc.
• PeptiStar Inc.
• PolyPeptide Group
• ScinoPharm Taiwan, Ltd.
• Teva Active Pharmaceutical Ingredients

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Peptide API Market to Reach US$33.5 Billion by 2030

The global market for Peptide API estimated at US$10.9 Billion in the year 2024, is expected to reach US$33.5 Billion by 2030, growing at a CAGR of 20.5% over the analysis period 2024-2030. GLP-1 Receptor Agonist, one of the segments analyzed in the report, is expected to record a 19.9% CAGR and reach US$17.6 Billion by the end of the analysis period. Growth in the Insulin segment is estimated at 21.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 27.4% CAGR

The Peptide API market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.9 Billion by the year 2030 trailing a CAGR of 27.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.5% and 18.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.2% CAGR.

Global Peptide API Market - Key Trends & Drivers Summarized

Why Are Peptide APIs Gaining Strategic Importance in Drug Discovery and Therapeutic Innovation?

Peptide Active Pharmaceutical Ingredients (APIs) have emerged as one of the most promising segments in modern drug development, offering high specificity, potency, and safety across a wide range of therapeutic indications. Derived from short chains of amino acids, peptide APIs are biologically active compounds that mimic endogenous molecules and interact with specific targets such as receptors, enzymes, and ion channels. Their unique mode of action, favorable pharmacokinetics, and low toxicity make them highly valuable in treating cancer, metabolic disorders, cardiovascular diseases, and rare genetic conditions.

The increasing success of peptide-based drugs such as liraglutide, semaglutide, buserelin, and leuprolide has demonstrated the clinical viability of peptides, propelling pharmaceutical firms to invest in specialized R&D and scalable manufacturing platforms. With the shift toward precision medicine and biologics, peptides are bridging the gap between small molecules and large proteins, offering opportunities for novel therapeutic modalities, including cell-penetrating peptides, peptide-drug conjugates, and multifunctional peptides. The expanding pipeline of peptide therapeutics across clinical phases underscores the rising demand for high-purity, cost-efficient peptide APIs.

How Are Advances in Synthesis Techniques and Process Optimization Enhancing API Manufacturing Capabilities?

The evolution of solid-phase peptide synthesis (SPPS), liquid-phase synthesis, and hybrid techniques has significantly improved the scalability, purity, and throughput of peptide API production. Automated peptide synthesizers, improved resins, and optimized coupling reagents now enable efficient synthesis of long, complex, and cyclic peptides with reduced reaction time and waste generation. Additionally, innovations in purification technologies such as preparative HPLC, ion-exchange chromatography, and ultrafiltration have enhanced yield and impurity control.

Manufacturers are investing in continuous manufacturing platforms and high-throughput parallel synthesis systems to reduce batch variability and enable rapid scale-up for clinical and commercial supply. Moreover, regulatory expectations for ICH Q11 compliance, process validation, and impurity profiling are driving the adoption of advanced analytics and quality-by-design (QbD) frameworks. Peptide modification strategies, including lipidation, PEGylation, and cyclization, are being integrated at the API stage to enhance bioavailability and stability. These advancements are improving cost-efficiency, regulatory compliance, and therapeutic performance across the peptide value chain.

Which Therapeutic Areas and Regional Markets Are Fueling Global Demand for Peptide APIs?

Metabolic diseases-especially Type 2 diabetes and obesity-remain the primary therapeutic drivers for peptide APIs, given the commercial success of GLP-1 analogs. Oncology, endocrinology, urology, and reproductive health are also major therapeutic domains utilizing peptides for hormone regulation, tumor suppression, and targeted therapy delivery. Peptides are increasingly being used in orphan drug development, vaccine formulations, and infectious disease management, including antimicrobial and antiviral applications.

North America and Europe dominate peptide API consumption due to strong biopharmaceutical pipelines, advanced manufacturing capabilities, and regulatory maturity. The U.S. leads in innovation, clinical trials, and commercialization, while Germany, Switzerland, and Belgium are major manufacturing hubs. Asia-Pacific-particularly India, China, South Korea, and Japan-is rapidly expanding its footprint as a cost-efficient supplier of peptide APIs and contract manufacturing services (CDMOs). Regional players are scaling up to meet the needs of both branded innovators and biosimilar developers, creating a globally integrated and competitive market landscape.

What Is Driving Long-Term Growth and Strategic Transformation in the Peptide API Market?

The growth in the peptide API market is driven by rising clinical success rates of peptide drugs, strong R&D investment in biologics, and increasing preference for targeted therapies. As pharmaceutical pipelines diversify and regulatory agencies encourage orphan drug development, peptide APIs are gaining ground as scalable, versatile therapeutic platforms. The global expansion of contract development and manufacturing services (CDMO) is also driving API outsourcing, with specialized peptide facilities in high demand for GMP-compliant, cost-competitive production.

Strategically, companies are adopting vertical integration, partnering with biotech firms for co-development, and investing in dual manufacturing sites for supply resilience. The convergence of peptide synthesis with computational biology, AI-based drug design, and nanotechnology is opening new frontiers in personalized medicine and advanced delivery systems. As regulatory frameworks continue to evolve to accommodate peptide therapeutics, API manufacturers that offer flexible, end-to-end solutions with robust quality systems are well-positioned to lead this high-growth segment.

SCOPE OF STUDY:

The report analyzes the Peptide API market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (GLP-1 Receptor Agonist, Insulin, Other Peptide Classes); Administration Route (Oral Route, Parenteral Route); Application (Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application, Non-alcoholic Fatty Liver Disease Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Aji Bio-Pharma Services
• AmbioPharm, Inc.
• Anthem Biosciences
• Bachem Holding AG
• Biocon Limited
• Biopeptek Pharmaceuticals
• CordenPharma International
• CPC Scientific Inc.
• Creative Peptides
• GenScript Biotech Corp.
• Hybio Pharmaceutical Co.
• Innovent Biologics
• Lonza Group AG
• Merck KGaA
• Peptide Institute, Inc.
• PeptiDream Inc.
• PeptiStar Inc.
• PolyPeptide Group
• ScinoPharm Taiwan, Ltd.
• Teva Active Pharmaceutical Ingredients

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Peptide API - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Adoption of Peptide-Based Therapeutics Propels Demand for High-Purity Peptide APIs
  • Expansion of Chronic Disease and Cancer Treatment Pipelines Drives Clinical Uptake of Peptide Drugs
  • Advancements in Solid-Phase Synthesis and Liquid-Phase Technologies Strengthen Manufacturing Scalability
  • Increased Outsourcing to CDMOs and CMOs Supports Cost-Efficient, Large-Volume API Production
  • Regulatory Support for Generic Peptides and Biosimilars Expands Addressable Market in Developing Regions
  • Integration of Automated Peptide Synthesizers Enhances Batch Reproducibility and Yield Optimization
  • Shift Toward Long-Acting Injectable Peptides Spurs Innovation in Sustained-Release API Formats
  • Surge in Personalized Medicine and Targeted Therapy Programs Throws the Spotlight on Custom Peptide APIs
  • Use of Novel Protecting Groups and Linkers Drives Improvement in Synthesis Efficiency and Product Stability
  • Growing Complexity of Multi-Peptide APIs Spurs Demand for Advanced Purification and Lyophilization Methods
  • Rising Investment in Peptide Drug Development Fuels Clinical Trial Activity and Commercial Pipeline
  • Expansion of GLP-1, GnRH, and Somatostatin Analog Classes Sustains Market Growth in Key Indications
  • Availability of GMP-Compliant Manufacturing Facilities Enhances Regulatory Approval Success Rates
  • Growing Focus on Peptide Oral Delivery Systems Encourages Innovation in Formulation Science
  • Strategic Collaborations Between Biotech Firms and API Manufacturers Accelerate Route-to-Market
  • Use of Peptide Conjugates and Fusion Molecules Expands Therapeutic Applications Across Disease Areas
  • Stringent Quality and Impurity Specifications Drive Investment in Analytical Testing Capabilities
  • Increase in Government Funding for Rare Disease Peptide Therapies Expands Innovation Incentives
  • Rising Demand for Cold Chain Storage and Transport of Peptide APIs Spurs Infrastructure Modernization
  • Emergence of Green Chemistry and Eco-Friendly Solvent Use Supports Sustainable Peptide Manufacturing
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Peptide API Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Peptide API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Peptide API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for GLP-1 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Peptide Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Peptide Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Peptide Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Type 2 Diabetes Mellitus Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Type 1 Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Type 1 Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Type 1 Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Obesity Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Non-alcoholic Fatty Liver Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Non-alcoholic Fatty Liver Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Non-alcoholic Fatty Liver Disease Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• JAPAN
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• CHINA
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• EUROPE
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Peptide API by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Peptide API by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• FRANCE
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• GERMANY
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Peptide API by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• INDIA
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Peptide API by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Peptide API by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Peptide API by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Peptide API by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• AFRICA
  • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030

IV. COMPETITION